Regenxbio Inc. Banner Image

Regenxbio Inc.

  • Ticker RGNX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Regenxbio Inc. Logo Image
  • 51-200 Employees
  • Based in Rockville, Maryland
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology LicenseesMore are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
4.8 / 5.0 (192)

Regenxbio Inc. reports have an aggregate usefulness score of 4.8 based on 192 reviews.

Regenxbio Inc.

Most Recent Annual Report

Regenxbio Inc.
MOST RECENT 2022 Annual Report and Form 10K

Regenxbio Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Regenxbio Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!